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ABSTRACT
Non-protein-coding RNAs (ncRNAs) fulfill a wide
range of cellular functions from protein synthesis
to regulation of gene expression. Identification
of novel regulatory ncRNAs by experimental
approaches commonly includes the generation of
specialized cDNA libraries encoding small ncRNA
species. However, such identification is severely
hampered by the presence of constitutively
expressed and highly abundant ‘house-keeping’
ncRNAs, such as ribosomal RNAs, small nuclear
RNAs or transfer RNAs. We have developed a novel
experimental strategy, designated as subtractive
hybridization of ncRNA transcripts (SHORT) to
specifically select and amplify novel regulatory
ncRNAs, which are only expressed at certain
stages or under specific growth conditions of
cells. The method is based on the selective
subtractive hybridization technique, formerly
applied to the detection of differentially expressed
mRNAs. As a model system, we applied SHORT to
Epstein–Barr virus (EBV) infected human B cells.
Thereby, we identified 21 novel as well as previously
reported ncRNA species to be up-regulated during
virus infection. Our method will serve as a powerful
tool to identify novel functional ncRNAs acting as
genetic switches in the regulation of fundamental
cellular processes such as development, tissue
differentiation or disease.
INTRODUCTION
In the recent past, the importance of the surprisingly
diverse class of non-coding RNA molecules (ncRNAs)
has been widely recognized (1–4). The key feature of all
ncRNAs is that they are not translated into proteins
but rather exert their functions at the RNA level.
NcRNAs have been identiﬁed in unexpectedly large
numbers, with present estimates—based on bioinformat-
ical approaches—in the range of many thousands per
eukaryal genome (5,6). They play key roles in a variety
of fundamental processes in all three domains of life,
that is Eukarya, Bacteria and Archaea. Their functions
include DNA replication and chromosome maintenance,
regulation of transcription, RNA processing, translation
and stability of mRNAs, and even regulation of stability
and translocation of proteins (7–10). Many ncRNAs
have been discovered fortuitously, suggesting they merely
represent the tip of the iceberg.
One of the most prominent and abundant ncRNA
classes consists of 21–23-nt long RNA species designated
as microRNAs (miRNA) (7). MiRNAs play a crucial role
in the posttranscriptional regulation of protein-coding
genes during development, diﬀerentiation and cellular
growth (7). In addition, viral or cellular encoded miRNAs
were found to be involved in infections by DNA or RNA
viruses (11–14). In the past, only very few ncRNAs,
in addition to miRNAs, have been identiﬁed, which
might be involved in the regulation of viral infections.
We thus investigated the small ncRNA transcriptome of
human B cells to identify ncRNAs expressed from the
viral or cellular genome upon Epstein–Barr virus (EBV)
infection.
Epstein–Barr virus, a DNA virus of the herpesviridae
family with a linear double-stranded genome of  172kb,
is associated with a heterogeneous group of human
tumors including Burkitt’s lymphoma (15). Until now,
a total of 25 EBV-encoded ncRNAs, including 23
EBV-encoded miRNAs (16,17) as well as two  170-nt
long ncRNA species, designated as EBER 1 and EBER 2
(18,19), have been identiﬁed.
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species can be achieved by bioinformatical or experimental
approaches or a combination of both (1,2,20). For
experimental approaches, the generation of specialized
cDNA libraries has been shown to represent a powerful
tool (20). However, identiﬁcation of novel ncRNAs is
often masked by a background of highly abundant cellular
‘house-keeping’ ncRNAs, such as ribosomal RNAs, small
nuclear RNAs or tRNAs. Thus, for identiﬁcation of novel
diﬀerentially expressed ncRNA candidates, e.g. those
expressed upon viral infections only, novel experimental
methods are required.
MATERIALS AND METHODS
Cells and EBVstrains
The non-adherent EBV-transformed B cell lines
B95.8-CBL (21) and BL41 (22) were cultured in RPMI
1640 supplemented with 10% FCS and antibiotics (100 U
penicillin ml
 1 and 100mg streptomycin ml
 1). BL41 is an
EBV-negative Burkitt’s lymphoma line, B95.8-CBL was
established by transformation of primary human cord
blood lymphocytes (CBLs) using the B95.8 strain of EBV.
Subtractive hybridization ofncRNA transcripts (SHORT)
Total RNA was isolated from the Burkitt’s lymphoma cell
line BL41 (driver RNA) and from CBLs immortalized
with the Epstein–Barr virus strain B95-8 (target RNA) by
the TRIzol method. From 150 to 200mg total RNA were
separated by denaturating 8% polyacrylamide gels and
size-fractionated by the excision of RNAs in the size
range between 20–70nt (small fraction) and 70–500nt
(large fraction). RNAs were passively eluted into 12ml
0.3M NaOAc (pH 5.2) over night at 48C, the eluate
ﬁltered trough a 0.2mm syringe ﬁlter and concentrated to
 200ml with the vivaspin 15R concentrator (Sartorius,
Goettingen, Germany) at 48C. Following ethanol pre-
cipitation and lyophilization of the RNA pellet, the
30-ends of 5mg of the size-selected RNAs were modiﬁed
using 5 units poly(A) polymerase (Invitrogen, Carlsbad,
CA, USA) at 378C for 1h in 50ml buﬀer containing
50mM Tris/Cl (pH 8.0), 200mM NaCl, 12mM MgCl2,
2mM MnCl2, 1mM DTT, 0.4mM EDTA and 40 units
ribonuclease inhibitor (Fermentas, Hanover, MD, USA).
The driver RNA was A-tailed in the presence of 4mM
ATP, while the target RNA was C-tailed by using 4mM
CTP instead. Subsequently, the 30-tailed RNAs were
phenol/chloroform extracted, ethanol precipitated and
resuspended in 7mlH 2O. Then the RNAs were treated
with 10 units tobacco acid pyrophosphatase (Epicentre)
for 1h at 378Ci n1 0ml buﬀer containing 50mM NaOAc
(pH 6.0), 1mM EDTA, 0.1% b-mercaptoethanol,
0.01% Triton X-100 and 40 units ribonuclease inhibitor.
Subsequent to phenol/chloroform extraction and ethanol
precipitation, the RNA pellets were dissolved in 10mlH 2O
and an adaptor was ligated to the 50-ends in a 20ml
reaction containing 50mM HEPES/NaOH (pH 8.0),
10mM MgCl2, 10mM DTT, 0.1mg/ml BSA, 20mM
adaptor, 1mM ATP, 40 units ribonuclease inhibitor and
10 units T4 RNA ligase (Fermentas) at 48C over night.
The sequences of the 50-DNA/RNA-hybrid-adapter were
ACGGAATTCCTCACTGAG and GTCAGCAATCCC
TAACGAG for the driver and target RNA, respectively,
whereas RNA nucleosides are underlined. After a second
phenol/chloroform extraction and ethanol precipitation,
the driver RNA was reverse transcribed employing 5mM
of the anchored primer TTTTTTTTTTTTTTTTTTTTN
(primer a), while for the target RNA the anchored primer
AGGAGCCATCGTATGTCGGGGGGGGGN (primer
b) was used in a 20ml reaction with 200 units reverse
transcriptase (Invitrogen) at 428C for 1h. 1/40 volume of
the driver cDNA was PCR ampliﬁed in 20 cycles by using
the two 50-biotinylated primers ACGGAATTCCTCAC
TGAG (primer c) and primer a. Subsequent to PCR
product puriﬁcation (QIAGEN, Valencia, CA, USA),
the DNA was eluted into 50mlH 2O. 25ml of this primary
PCR was then used in an ‘unequal PCR’ reaction with
10mM of the 50-biotinylated primer c as the sole primer,
which linearly ampliﬁed the (þ)-strand that corresponds
to the sequence of the original driver RNA. After 20 cycles
the 50-biotinylated DNA was puriﬁed (QIAGEN), eluted
into 50mlH 2O and lyophilized. 15ml of the reverse
transcribed target RNA was diluted with H2Ot o4 5 ml
and the target RNA template was hydrolyzed by adding
5ml 1M NaOH and incubation at 708C for 20min.
Subsequently to the neutralization by adding 45mlH 2O
and 5ml 1M HCl, the single stranded target cDNA was
puriﬁed (QIAGEN), eluted into 50mlH 2O, lyophilized
and dissolved in 15mlH 2O.
For the subtractive hybridization, 5ml of the single
stranded target cDNA was used to redissolve the pellet
of the 50-biotinylated driver DNA. The molar ratio
between driver and target was calculated to be  50000:1.
After the addition of 5mlo fH 2O, the driver and target
were allowed to hybridize by heating to 988C for 3min,
followed by incubations at 658C for 2min and 428C for
15min. Subsequently the volume was increased to 20ml
and the buﬀer adjusted to 5mM Tris/Cl (pH 7.5), 1.0M
NaCl and 0.5mM EDTA before mixing the sample with
10ml strepavidin coated magnetic beads (Dynal Biotech,
Oslo, Norway). The sample was vortexed for 15min at
258C before the tube was placed in a magnet for 3min to
allow bead separation. The supernatant, containing
single stranded target cDNA that was not captured via
the 50-biotinylated driver, was removed and used for a
consecutive round of subtractive hybridization using
fresh 50-biotinylated driver DNA. After the ﬁfth round,
the target cDNA was PCR ampliﬁed using the forward
and reverse primer pair GTCAGCAATCCCTAACGAG
(primer d) and AGGAGCCATCGTATGTCG (primer e),
respectively, and cloned into the pGEM-T vector
(Promega, Mannheim, Germany). This experimental
design, applying ﬁve rounds of SHORT, can be performed
in one working day. Theoretically more rounds can
be envisioned, however it is of note that with every
round of SHORT, the problem of target cDNA dilution
increases. In addition we found that the bands in
the control PCRs done after every round of SHORT
did not change signiﬁcantly after the fourth round
(data not shown).
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cDNA clones were sequenced and the sequences were
analyzed with the LASERGENE sequence analysis
program package (DNASTAR, Madison, WI, USA) as
described (23).
Northern blot analysis
Total RNA (20–30mg) from the non-infected B cell line
BL41 or the EBV-infected cell line B95.8-CBL were
separated on 8% denaturing polyacrylamide gels
(7M urea, 1  TBE buﬀer), transferred onto nylon
membranes and probed with 50-[
32P] end-labeled antisense
DNA probes as described (23). Northern blot signals
were quantiﬁed using a Molecular Dynamics Storm
PhosphorImager (Image quant software version 5.0).
All quantiﬁed northern blot signals were normalized to
the band intensities of the 5.8S rRNA loading control.
Comparison of the quantiﬁed northern blot bands form
EBV-infected to the uninfected control revealed the level
of up-, or down-regulation.
RESULTS
In order to identify diﬀerentially expressed ncRNAs
(from the EBV genome or from the cellular genome),
we have adapted an experimental approach, designated as
‘subtractive hybridization’, which previously has been
applied to the identiﬁcation of diﬀerentially expressed
mRNAs (24). By this new method, which we named
‘SHORT’, diﬀerentially expressed ncRNAs, in the size
range from 20 to 500nt, are signiﬁcantly enriched in
a size selected cDNA library encoding small ncRNAs
(for a detailed description see Figure 1 and Materials
and Methods section). NcRNAs were subdivided into
two fractions, in the size range between 20–70nt (small
fraction) and 70–500nt (large fraction), since smaller
cDNA species are known to be more eﬃciently cloned into
plasmid vectors than longer cDNAs.
The general principle of the subtractive hybridization
technique is the use of excess amounts of RNA transcripts
from control cells (in our case from uninfected B cells, also
designated as driver cells) for hybridization with limiting
amounts of single-stranded cDNAs generated from
RNA transcripts of the target cells (i.e. EBV-infected
human B cells). The conceptual novelty of SHORT can
be highlighted as follows: since ncRNAs are usually not
poly-adenylated, for reverse transcription of RNAs
poly(A) or poly(C) tails, respectively, were added at
their 30-ends (20) (Figure 1). In addition, adaptor
sequences were added to the 50-ends of both driver and
target transcripts to generate PCR priming sites. As many
Figure 1. The principle of SHORT. Total driver RNA from
non-infected cells was size-selected by denaturing PAGE to obtain
RNAs in the size range from 20 to 500nt. Size-selected RNAs were
30 poly-adenylated using poly(A) polymerase (step i). Subsequently,
a DNA/RNA adaptor oligonucleotide was ligated to the 50-ends of the
ncRNAs which served as a 50-primer site in an RT-PCR reaction
(step ii). RT-PCR was performed using an anchored oligo (dT)-primer
complementary to the 30 poly(A)-tail and a 50-biotinylated adaptor
primer as forward primer (step iii). The biotin moiety is shown as blue
asterisk. Resulting cDNAs were used as templates in an unequal PCR
reaction using excess amounts of 50-biotinylated adaptor primer to
linearly amplify single-stranded and 50-biotinylated sense cDNA copies
(step iv). Target RNA, derived from EBV-infected cells, was C-tailed at
the 30-ends (step v). The 50-ends of the target ncRNAs were ligated to
an RNA/DNA oligonucleotide linker that diﬀers in sequence from
the one used for ampliﬁcation of the driver RNA (step vi). C-tailed
target RNAs were subsequently reverse transcribed into single stranded
cDNAs by an anchored oligo d(G) primer (step vii) and allowed to
hybridize with excess of the single stranded and biotinylated driver
DNA (step viii). Transcripts that are equally expressed in both driver
and target cells form duplexes and thus were captured via the 50-biotin
moiety of the driver-DNA on streptavidin-coated magnetic beads
(step ix). Target cell speciﬁc transcripts (red) remained single stranded
and were therefore enriched in the supernatant (step x). In order to
increase the selective eﬃciency of SHORT, subtractive hybridization
(steps viii to x) was repeated four times.
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hybridization and since, in addition, RNA is known to
be thermally more unstable than DNA, we converted both
the driver and target RNAs into single-stranded sense- or
anti-sense cDNAs, respectively. The conversion of the
driver RNA into cDNA has the additional advantage that
driver transcripts can be ampliﬁed by RT-PCR prior to
conversion into single-stranded sense cDNAs. Therefore,
a large access of driver DNA over target DNA can be
employed in the selective hybridization step. This might
be especially important in cases where the amount of
cellular RNA is limited. Subsequently, driver and target
cDNAs were allowed to hybridize (Figure 1). cDNA
species derived from ncRNAs that are equally expressed
in both cells form duplexes. Since driver cDNAs were
generated to contain a biotin moiety at their 50-ends,
cDNA duplexes could be captured on streptavidin-coated
magnetic beads (Figure 1). Target cell speciﬁc transcripts
remained single stranded and therefore became enriched
in the supernatant.
To verify selective ampliﬁcation of virus-induced
ncRNAs, cDNAs in the supernatant were PCR-ampliﬁed
and size-separated by PAGE and compared to the
unsubtracted target cDNA pool from step vii) of
Figure 1. In both analyzed size fractions (i.e. from 20 to
70nt: small fraction and from 70 to 500nt: large fraction),
PCR-derived DNA patterns diﬀered considerably in size
and abundance compared to the unsubtracted target
control sample (Figure 2a). This is consistent with the
SHORT method reducing or eliminating abundant
cDNA species, present in both driver and target pools.
After ﬁve subtraction rounds of SHORT, we cloned
PCR-ampliﬁed cDNAs and sequenced a small number of
 250 clones from each cDNA library (20). In total, we
analyzed 506 sequences, which were grouped into 208
unique sequences (designated as contigs). Sequence
analysis conﬁrmed that SHORT changed the cDNA
proﬁle of the subtracted cDNA library compared to the
unsubtracted control cDNA library: while in the unsub-
tracted library of the large ncRNA fraction 85% of all
sequences originated from known ‘house-keeping’
ncRNAs (such as tRNAs, 28S rRNA, 5.8S rRNA and
5S rRNA), this group was signiﬁcantly reduced to only
23% after SHORT (Figure 2b). Conversely, the fraction
of potential novel ncRNA candidates and EBV-encoded
ncRNAs increased from 10 to 40% of analyzed sequences.
The fact that 7% of sequences in the subtracted cDNA
library originated from the EBV-encoded transcripts
EBER 1 and 2 served as a valuable internal control for
speciﬁc ncRNA enrichment, since in the unsubtracted
cDNA library control (in which cDNAs were also derived
from EBV-infected cells), not a single EBV-encoded
cDNA sequence could be identiﬁed (Figure 2b).
Sequence analysis of the small fraction also revealed that
house-keeping ncRNAs present in both driver and target
pools could be reduced (data not shown). Notably, from
217 analyzable sequences of the small fraction, 81
sequences (or 37%) belong to the class of miRNAs.
Twenty-three cDNA sequences (11%) could not be
assigned to any known class of ncRNAs and thus
represent potentially candidates for novel ncRNA species.
Figure 2. SHORT changes the small ncRNA transcriptome. (a) cDNAs
originating from ncRNAs of EBV-infected B cells were PCR ampliﬁed
before ( ) or after (þ) ﬁve rounds of subtractive hybridization
(SHORT) and applied on a denaturing polyacrylamide gel. The
cDNAs in the size range between  120–500nt (large fraction) and
 70–120nt (small fraction) that were cut out, eluted and cloned into
the pGEM-T vector are indicated by white bars. (b) Sequencing results
of 250 clones of the large fraction library (originating from ncRNAs in
the size range between 70 and 500nt) of EBV-infected cells after
ﬁve rounds of SHORT is compared to  70 clones of the unsubtracted
EBV-infected library. SHORT changed the ncRNA transcriptome
signiﬁcantly since the fraction of potentially interesting ncRNAs
(including new ncRNA candidates and EBV-derived sequences)
increased from 10% in the unsubtracted, to 40% in the subtracted
library. Concomitantly, the fraction of known ‘house-keeping’ ncRNAs
(especially tRNAs and rRNAs) decreased dramatically (from 85
to 23%).
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are indeed diﬀerentially expressed upon EBV infection,
we chose 14 candidates from the large and 23 candidates
from the small fraction from the ‘non-house-keeping’
ncRNA classes and investigated their expression levels by
northern blot analysis. Thereby, expression of 29% of
ncRNAs from the large and 26% of the sequences from
the small fraction libraries were shown to be signiﬁcantly
up-regulated in the EBV-infected cell line compared to
uninfected cells (Figure 3).
In particular, host cell-encoded vault associated
ncRNAs 1–3 (98, 88 and 88nt in size, respectively), were
up-regulated by at least 1200-, 20- and 40-fold, respec-
tively, in EBV-infected cells (Figure 3). Interestingly,
in our screen we also have identiﬁed a novel ncRNA
candidate (termed CBL-3), which were 4-fold up-regulated
in EBV-infected cells compared to uninfected cells
(Figure 3 and Table 1). CBL-3 shares compelling sequence
and structural similarities with the known vault RNAs
(vRNAs) (Figure 4). Furthermore, vRNA 1 and this
putative novel vRNA (CBL-3) were found to be sig-
niﬁcantly up-regulated also in another B cell line, namely
when comparing non-infected to EBV-infected BL2 cells
(data not shown). Expression of vRNAs does not appear
to be a general cellular response mechanism to viral
infections, since in HIV infected T-cells we could not
detect a comparable up-regulation of vRNAs (data
not shown).
In addition to vault ncRNAs, we also identiﬁed two
other novel ncRNA candidates from the large cDNA
library up-regulated in EBV-infected B cells. The ﬁrst
RNA is a 144-nt long ncRNA transcript encoded on
chromosome 19 (CBL-1) whose expression was stimulated
4-fold upon EBV infection (Figure 3a and Table 1).
Interestingly, 14 diﬀerent gene copies of CBL-1 could be
identiﬁed on chromosome 19 mapping within a region of
2.2 Mb which are encoded on the plus or minus strand,
respectively (Figure 5). Sequence identities of the various
paralogs range from 98.3 to 100%. The second novel
Figure 3. Northern blot analysis of diﬀerentially expressed ncRNA
candidates. (a) Northern blot scans of ncRNAs in uninfected BL41
(EBV ) and EBV-infected CBL cells (EBVþ) are shown for the large
(RNAs between 70 and 500nt) and the small (20–70nt) fraction.
The size of the ncRNAs, as estimated by comparison with an internal
RNA marker, is indicated on the right. Names of ncRNA candidates
are in red and black for host- and EBV-encoded species, respectively.
Novel ncRNA candidates identiﬁed in this study are referred to as
CBL-1–5 (for cord blood lymphocyte derived ncRNAs). The 5.8S
rRNA serves as internal RNA loading control. (b) Quantiﬁcation of
ncRNA expression of diﬀerentially expressed transcripts. The name and
class of all diﬀerentially expressed ncRNAs identiﬁed in this study are
indicated as well as the extend of up-(") regulation in the EBV-infected
cell line (EBV
þ) compared to the uninfected control. Novel ncRNA
candidates are shown with grey background and EBV-encoded
transcripts are underlined.
Table 1. Novel ncRNA candidates
Sequence cDNA (nt) N. blot (nt) Remarks
CBL-1 GGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGG
GCCCTCACGGAGGCGGGGGTTCCAGGGCACGAGTTCGA
GGCCAGCCTGGTCCACATGGGTCGGAAAAAAGGATTT
114 114 Repeated locus on
chromosome 19; intergenic
CBL-2 ATAGACAGCGTGGTCTAGTGGTTAAGAGCACAAGGCTT
GGGAGCCAGACTTCCTGGGTTTAAACTCGAGTACCACC
ATTAACTAGCCATGCATT
94 94 Encoded in an intergenic
locus on chromosome 8
CBL-3 CCCGGGTCGGAGTTAGCTCAAGCGGTTACCTCCTCATG
CCGGACTTTCTATCTGTCCATCTCTGTGCTGGGGTTCG
AGACCCGCGGGTGCTTACTGACCCTTTT
104 100 Encoded in an intergenic
locus on chromosome 5;
similarities to vault RNAs
CBL-4 AACAGCAGCCAATAGCTGGTTGGCATTCTGGCCCTGG
TTCATGCCAACTCTTGTGTTGACTACCCCAGGATG
CCAGCATAGTT
83 133 Encoded in the second
intron of the MATR3
gene on chromosome 5
CBL-5 GCTGTCATTGCTACACTGGAGTCA 24 22 Intergenic locus on
chromosome 3
The sequence lengths of the ﬁve novel ncRNA candidates (CBL-1–5) in the cDNA library as well as the estimated lengths of the bands on the
northern blot scans (N. blot) are indicated.
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up-regulated 4-fold in EBV-infected B cells (Figure 3).
CBL-2 is predicted to map to a locus encoding a MIR
subclass of small interspersed nuclear elements (SINE),
however expression of the repeat has not been experimen-
tally conﬁrmed, up till now.
From the small-size cDNA library (derived from
ncRNAs sized from 20 to 70nt), a highly up-regulated
ncRNA (by 29-fold) in the EBV-infected cell line was
identiﬁed as the host-encoded miRNA-155 (Figure 3).
This miRNA species is processed form a larger RNA
precursor transcript, previously designated as BIC RNA,
and has recently been shown to be up-regulated up
to 30-fold in human B cell lymphomas (26). The
abundance of miRNA-155 in our SHORT cDNA
library (represented by 25% of all cDNA clones from
the small fraction library) clearly points to the potential
of this method to selectively amplify, and thus identify,
known over-expressed ncRNA transcripts of target
B cells.
Figure 4. Secondary structure predictions of vault RNA 1–3 and CBL-3. The three known human vault associated RNAs (vRNA 1-3) and the novel
ncRNA candidate CBL-3 were folded using the RNAfold algorithm developed by Hofacker and et al. (25). The characteristic internal polymerase III
promoter elements, A-box and B-box, are colored red and blue, respectively.
Figure 5. Genomic location of the new ncRNA candidate CBL-1. CBL-1 is encoded in 14 copies (red arrows) on human chromosome 19 spanning
a region of 2.2 Mb. The location on the chromosome is given according to the UCSC Genome Browser coordinates. The distances between the
individual CBL-1 repeats are given above the arrows.
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up-regulated (by 7-fold) in EBV-infected cells (Figure 3).
miRNA-21 is encoded on chromosome 17 and its
up-regulation has been suggested to play a general role
in cell diﬀerentiation (27,28). Recently it has been reported
that miRNA-21 functions as an oncogene and modulates
tumorgenesis in breast tumor tissues (29). To our knowl-
edge, our ﬁndings are the ﬁrst evidence of miRNA-21
being over-expressed upon viral infection in human
lymphocytes.
Other up-regulated miRNAs were miRNA-146a
(10-fold) and miRNA-29b (2-fold) (Figure 3). In addition
to those known miRNA we also identiﬁed one potential
novel miRNA candidate. Northern blotting revealed
that the 22-nt long ncRNA CBL-5 was up-regulated
upon EBV infection by 3-fold (Figure 3). The ncRNA
candidate is encoded on chromosome 3, but lacks the
canonical fold of a bona ﬁde miRNA precursor structure
(data not shown).
Besides host-encoded miRNAs, we also identiﬁed four
of the previously described EBV-encoded miRNAs (13,16)
(BART4, BART1-3p, BHRF1-1 and BHRF1-2) in our
subtracted library (Figure 3). Lack of identiﬁcation of the
remaining 19 known EBV-encoded miRNAs is largely due
to the EBV strain used (B95-8) lacking a genomic segment
encoding 15 known miRNAs (17).
In addition to ncRNA species, up-regulated upon viral
infection, we also observed novel ncRNA candidates in
the SHORT subjected library whose expression did not
change (CBL-4) (Table 1) or whose expression was even
found to be down-regulated. MiRNAs miR-20b, miR-15a
and miR-15b were found to be 3- to 4-fold less eﬃciently
expressed in the EBV-infected cell line. This might be
explained by the elimination of abundant ‘house-keeping’
ncRNAs by SHORT, which in turn generally increases
the probability of identifying novel ncRNA species in
cDNA libraries.
DISCUSSION
By applying the SHORT method to an EBV-infected
B-cell line and subsequent sequence analysis of a rather
small number of 506 cDNA clones, we have identiﬁed 208
unique ncRNA sequences, including ﬁve novel ncRNA
candidates (Table 1). From these, we selected 37 ncRNAs
and analyzed their expression levels by northern
blot analysis. 21 ncRNAs (57%) were shown to be
up-regulated upon EBV infection (Figure 3). It is strongly
anticipated that SHORT in combination with high-
throughput deep-sequencing analysis of the subtracted
cDNA library will result in the identiﬁcation of an even
higher number of diﬀerentially expressed ncRNA
candidates.
Especially intriguing was the identiﬁcation of the
B cell-encoded three vault ncRNAs shown to be
extensively up-regulated during EBV infection (by up to
1200-fold). vRNAs have been reported previously to serve
as integral parts of a so-called vault complex, a large
hollow barrel-shaped ribonucleo-protein complex (RNP)
with a size of 13 MDa (30). The vault RNP particle is
found in numerous higher eukaryal species as diverse
as mammals, avians, amphibians, ﬁsh, echinoderms,
mollusks as well as in lower eukarya such as the slime
mold Dictyostelium discoideum and in protozoa (30).
The vault complex consists of multiple copies of three
diﬀerent highly conserved proteins and at least six copies
of vRNAs (31). At present the expression of three vRNA
genes (HVG1-3) has been demonstrated experimentally
while a fourth putative vRNA gene (HVG4) has been
identiﬁed by homology search whose expression could not
be observed (32). The putative novel vRNA (CBL-3) that
we have identiﬁed this study (see above and Figure 4),
however, is not related to the HVG4 locus.
vRNAs have been reported to locate at the two cap
structures closing the barrel-shaped mid-section of the
vault complex. RNase-treatment of vault complexes
has been shown to have no apparent eﬀect on morphology
of the vault RNP, implying that the vRNAs might possess
functional rather than structural roles in the vault complex
(31). The vault RNP has previously been proposed to be
involved in nucleo-cytoplasmic transport and implicated
in intracellular detoxiﬁcation processes and hence in
multidrug resistance in cancer cells (33,34). For localiza-
tion of vRNAs, we performed ﬂuorescence in situ
hybridization experiments employing antisense probes
directed against vRNA 1. These experiments demon-
strated that vRNA 1 localizes close to the nucleus in EBV-
infected B cells (data not shown), consistent with earlier
ﬁndings indicating that vault RNP associates with nuclear
pores in various mammalian cell lines (30,35–38). It is
tempting to speculate that vRNAs might be involved in
anti-viral defense and/or transport mechanisms.
We also observed up-regulation (by up to 29-fold) from
seven previously reported miRNAs, as well as a novel
miRNA candidate not previously annotated. Two of these
miRNA species, miR-21 and miR-155, have previously
been implicated in human cancers (26,29). Our data point
to the possibility that they might also be involved in viral
infections. MiRNAs have been shown to regulate the gene
expression in mammals, including humans, by binding to
the 30-untranslated region (UTR) of mRNAs thus repress-
ing their translation (7). Thereby, single miRNA species
were suggested to target up to 100–200 diﬀerent UTRs
within mRNAs, however for the majority of predicted
targets experimental evidence is lacking (39,40). For
example, by employing the miRNA-target search tool
from the Sanger Centre (http://microrna.sanger.ac.uk/
targets/v4/), genes involved in tumor suppression, such
as the tropomyosin 1 gene (TPM1), were identiﬁed as
potential targets for miR-21. In addition, RGS1, a gene
encoding B cell activation protein BL34, was identiﬁed as
a potential target for miR-23a. It will be interesting to
assess experimentally whether predicted mRNAs, targeted
by miRNAs identiﬁed in our screen, are directly involved
in viral infection and/or defense mechanisms.
In summary, the considerable advantage of SHORT,
compared to standard experimental RNomics approaches
(20), is that it focuses on diﬀerentially expressed ncRNA
genes and therefore avoids the time-consuming and
cost-intensive multiple sequencing of already known and
constitutively expressed ncRNAs. Furthermore, removal
PAGE 7 OF 9 Nucleic Acids Research, 2007, Vol. 35, No. 10 e73of the majority of these ‘house-keeping’ transcripts by
SHORT increases the chance to identify low abundant
and so far unidentiﬁed ncRNA candidates, an advantage
that cannot be used in ncRNA micro array screens.
We demonstrate that SHORT can be applied to enrich
ncRNAs of human B cells in the size range from 22 to
300nt, a range that covers many of the known functional
small ncRNA classes from miRNAs (21 nts), snoRNAs
( 80–200nt) up to 7SL RNA ( 300 nts). Since SHORT is
performed exclusively in vitro, requires only minimal
amounts of starting ncRNAs and does not depend on
the source of the ncRNA transcripts, it is reasonable to
assume that this technique can be applied to other cells,
tissues or organisms as well. Thus, this procedure will
likely result in the identiﬁcation of novel regulatory
ncRNA species involved in diseases like cancer as well
as those which regulate fundamental cellular processes
such as development or tissue diﬀerentiation.
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